Clinical Trial Search

Primary: Crude Incidence Rate of Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) Per 1000 Person-years by Age — 0.01; 0.01; 0.03; 0.12 incidence rate per 1000 person-years

Primary: Change in Visual Acuity — 4; 3 lines change in Snellen chart

Primary: Change From Baseline in Visual Acuity at 9 Month — -0.0574; 0.0535 LogMAR

Primary: Number of Days Exposed to PDE5i During 1-Day Case Window and 29 1-Day Control Windows Among Participants Adjudicated as Definite NAION Cases — 14; 248 exposed days…

Primary: Mean Increase From Baseline in ETDRS Letters Read at 26 Weeks and Off-drug Follow-up Visit — 15; 7; 9; 6 EDTRS Letters

Primary: 30-Day Person Time Analysis Risk of NAION Associated With PDE5 Inhibitor Use — 2.27 Relative risk of exposure

Primary: Percentage of Patients With a Visual Field Improvement in the Study Eye — 12.0; 9.5; 4.2 Percentage of Patients

Primary: Number of Participants With Change/Improvement Visual Acuity From the Beseline — 28; 3; 5 Participants

Primary: Change in Full-field Visual Evoked Potential (FF-VEP) Latency at Week 24: Intent-to-treat (ITT) Population — 20.83; 17.34 msec — p=0.3337

Primary: Retinal Nerve Fiber Layer Thickness at Baseline and Month 6 — 128.1; 130.5; 89.5; 88.0 µm

Primary: Retinal Ganglion Cell Inner Plexiform Layer Thickness — 36.56; 34.65; 31; 29.42 micron

Primary: Change From Baseline in Raw Intraocular Pressure (IOP) by Visit — -3.20; -3.12; -3.22; -3.43 mmHg

Primary: Number of Participants With An Improvement in Vision, as Measured by an Increase of 15 Letters on the Early Treatment Diabetic Retinopathy Study (EDTRS) Vision Chart…

Primary: Change From Baseline in Visual Acuity (VA) at Final Visit — 0.61; 0.15 logMAR

Primary: Radical Peripapillary Capillaries Vessel Density — 55.95; 57.24 percentage of vessel

Primary: Incidence of Adverse Events — 3; 4 Participants

Primary: Change in the OHQ (Orthostatic Hypotension Questionnaire) Composite Score — 4.61; 4.17; 3.35; 3.5 Score on a scale

Primary: Number of Patients With no Disease Activity at Week 16 in the Study Eye — 89 Participants

Primary: Area of Lesion Measured by Optical Coherence Tomography Angiography (OCTA) Scan. — 1.07 mm^2

Primary: Changes in Vessel Density in Treatment Groups Assessed by OCT Angiography — -0.51; 2.59; -0.96; 0.96 percent change

Primary: Detection Accuracy (DA) Change in Percent Over Baseline Within Defective Visual Field Sectors — 24.75; 39.16 percent change

Primary: Post-operative Clinical Findings of Cystoid Macular Edema — 8.85; 8.95 mm

Primary: Change in Visual Acuity (Sildenafil Group) — 0.00; -0.03 logMAR

Primary: Number of Adverse Events at Six Months Post-Implantation — 10 Adverse Events

Primary: The Change in Best-corrected Visual Acuity (BCVA) From Baseline to Year 2 for All Participants. — 0.2; -11.3 ETDRS Letters

Primary: Change in Measurement in Central Macular Thickness Measured by Spectral Domain Optical Coherence Tomography( OCT) at One Month — -25.2; -29.9; -58.9 micrometers — p=0.04

Primary: Mean Change in Optical Coherence Tomography Measure Retinal Volume, mm3 — 0.02; -0.03 mm3

Primary: Blood Oxygenation — 60; 60; 60 percentage of oxygenation

Primary: Volume of New FLAIR Lesions(MRI) — 915; 477 mm^3 — p=0.445

Primary: Cure at Day 14 — 94; 97; 24; 50 Participants — p=0.0005